All News

NBC News Medical Analyst Vin Gupta, MD, joins Drug Topics at NCPDP 2025 to discuss the technological evolution of the pharmacy profession.

Attorneys from The Phoenix Law Group joined Drug Topics at NCPDP 2025 to discuss the current state of pharmacy benefit manager reform and where it may end up in the near future.

Abbott’s continuous glucose monitoring system is the first to show a reduction in cardiovascular complication severity.

The NCPDP’s Executive Vice President of Innovation & Standards joins Drug Topics to discuss how AI has been making itself known within the pharmacy profession.

However, investigators find many gaps remaining in care for patients in relation to race, ethnicity, and disabilities.

Investigators also find that patients diagnosed with type 1 diabetes later in life do not have a better prognosis compared to those diagnosed earlier.

Rick Sage, Executive Vice President of Innovation & Standards at NCPDP, discusses his role and how his team is using innovation to support the pharmacy profession.

Dae Lee, PharmD, Esq, CPBS and Lucas Morgan, Esq, discuss PBM and board of pharmacy enforcement actions, trends in PBM audits, and more.

Larry King, PharmD, joins Drug Topics at NCPDP 2025 to discuss pharmacy interoperability, changes in its regulations, and how technology will fall into place within the data infrastructure.

Investigators also found that nocturnal hypoglycemia is a strong predictor of daytime hypoglycemia.

Pharmacist-led interventions improve medication adherence compared with the usual care for patients with heart failure and type 2 diabetes.

In the second part of our interview with Miranda Rochol, she discusses challenges regarding digital prescription solutions and the financial burdens these solutions are designed for pharmacists to overcome.

In her expertise as a leader with the American Pharmacists Association, Brigid Groves, PharmD, MS, provides insights into her work with geographical information systems and maps.

Semaglutide resulted in a significant reduction in the risk of MACE within the first 3 months of treatment compared to placebo.

Vin Gupta, MD, discusses trends and perspectives in patient data privacy as well as what a “smart pharmacy” may look like in the near future.

Patients with psychosis, depression, and anxiety exhibit higher rates of vaccine hesitancy.

Greg Miller, RPh, discussed the past, present, and future of the Inflation Reduction Act and key insights pharmacists should understand in order to keep up with the legislation.

Cami Agena, Esq, and Candida Ruesga, Esq, discuss pharmacy benefit manager reform by providing insights from their experience as legal partners in complex PBM matters.

In a phase 3 study, 57% of patients treated with icotrokinra achieved an Investigator's Global Assessment score of 1 or 0 and a grade 2 or more improvement at week 16.

Tirzepatide (Zepbound) demonstrated superiority compared to semaglutide (Wegovy) across the primary end point and 5 key secondary end points.

Larry King, PharmD, discusses how pharmacy interoperability is working to create collaborative care and get pharmacists “in the game” as he says.

The order is set to make patients’ prescription costs similar to other nations with the lowest-priced drugs in the world.

Investigators find that unhealthy eating and inadequate or excessive sleeping duration could contribute to developing diabetic nephropathy.

Douglas Hoey, CEO of NCPA, discusses what independent pharmacies can do to handle an influx of patients and what the chain’s situation means for the pharmacy landscape.

The Summit provides a rare opportunity for professionals to dive deep into emerging healthcare technologies and treatment models.

Vin Gupta, MD, former Chief Medical Officer at Amazon Pharmacy and renowned US medical analyst, discusses pharmacists’ ability to reach communities and address social determinants of health.

Stanley V. Campbell, Jr., CEO of EagleForce Associates, Inc., and Yi Deng, PhD, Senior Vice President of Engineering at EagleForce, discuss the basics of AI and how it’s assisting with compliance.

The therapy achieved positive results during a phase 2b trial on the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score.